The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Aardvark Therapeutics Inc shares valued at $20,000,000 were purchased by Decheng Capital Global Life Sc on Feb 14 ’25. At $16.00 per share, Decheng Capital Global Life Sc acquired 1,250,000 shares. The insider’s holdings grew to 2,958,887 shares worth approximately $35.74 million following the completion of this transaction.
Also, Lee Tien-Li purchased 16,542 shares, netting a total of over 264,672 in proceeds. Following the buying of shares at $16.00 each, the insider now holds 1,496,175 shares.
Before that, Sun Nelson had added 10,000 shares to its account. In a trade valued at $160,000, the Chief Financial Officer bought Aardvark Therapeutics Inc shares for $16.00 each. Upon closing the transaction, the insider’s holdings increased to 10,000 shares, worth approximately $1.2 million.
As published in their initiating research note from RBC Capital Mkts on March 10, 2025, Aardvark Therapeutics Inc [AARD] has been an Outperform and the price target has been revised to $21. Analysts at Morgan Stanley started covering the stock with ‘”an Overweight”‘ outlook in a report released in early March. As of March 10, 2025, Cantor Fitzgerald has initiated its “an Overweight” rating for AARD. Earlier on March 10, 2025, BofA Securities initiated its rating. Their recommendation was “a Buy” for AARD stock.
Analyzing AARD Stock Performance
On last trading session,, Aardvark Therapeutics Inc [NASDAQ: AARD] rose 7.19% to $12.08. During the last five days, there has been a surge of approximately 7.00%. Over the course of the year, Aardvark Therapeutics Inc shares have dropped approximately -15.58%.
Support And Resistance Levels for Aardvark Therapeutics Inc (AARD)
According to the 24-hour chart, there is a support level at 11.35, which, if violated, would cause prices to drop to 10.61. In the upper region, resistance lies at 12.50. The next price resistance is at 12.91. RSI (Relative Strength Index) is 60.57 on the 14-day chart, showing neutral technical sentiment.
Which companies own the most shares of Aardvark Therapeutics Inc (AARD)?
In terms of Aardvark Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 29 in the next 12 months, up nearly 157.32% from the previous closing price of $11.27. Analysts anticipate Aardvark Therapeutics Inc stock to reach 29 by 2025, with the lowest price target being 29.
